|
US20160279239A1
(en)
|
2011-05-02 |
2016-09-29 |
Immunomedics, Inc. |
Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease
|
|
US20160355591A1
(en)
|
2011-05-02 |
2016-12-08 |
Immunomedics, Inc. |
Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
|
|
TW200838559A
(en)
*
|
2006-11-29 |
2008-10-01 |
Imclone Systems Inc |
Insulin-like growth factor-1 receptor antagonists for modulation of weight and liposity
|
|
PE20090368A1
(es)
|
2007-06-19 |
2009-04-28 |
Boehringer Ingelheim Int |
Anticuerpos anti-igf
|
|
CN105646643A
(zh)
|
2008-10-29 |
2016-06-08 |
阿布林克斯公司 |
单域抗原结合性分子的纯化方法
|
|
RU2481824C2
(ru)
|
2008-10-29 |
2013-05-20 |
Аблинкс Н.В |
Препараты однодоменных антигенсвязывающих молекул
|
|
WO2010056804A1
(en)
*
|
2008-11-12 |
2010-05-20 |
Medimmune, Llc |
Antibody formulation
|
|
EP2196476A1
(en)
*
|
2008-12-10 |
2010-06-16 |
Novartis Ag |
Antibody formulation
|
|
UY32317A
(es)
|
2008-12-12 |
2010-07-30 |
Boehringer Ingelheim Int |
Anticuerpos anti-igf
|
|
AR080428A1
(es)
|
2010-01-20 |
2012-04-11 |
Chugai Pharmaceutical Co Ltd |
Formulaciones liquidas estabilizadas contentivas de anticuerpos
|
|
WO2012028683A1
(en)
|
2010-09-02 |
2012-03-08 |
Novartis Ag |
Antibody gel system for sustained drug delivery
|
|
PL2616090T3
(pl)
|
2010-09-17 |
2023-12-18 |
Takeda Pharmaceutical Company Limited |
Stabilizowanie immunoglobulin poprzez wodną formulację z histydyną o ph od słabo kwaśnego do obojętnego
|
|
AU2011325134B2
(en)
|
2010-11-05 |
2014-10-23 |
Novartis Ag |
Methods of treating rheumatoid arthritis using IL-17 antagonists
|
|
AU2012250924B2
(en)
|
2011-05-02 |
2017-05-25 |
Immunomedics, Inc. |
Ultrafiltration concentration of allotype selected antibodies for small-volume administration
|
|
AU2012328753A1
(en)
*
|
2011-10-26 |
2014-04-24 |
Amgen Inc. |
Methods of reducing or eliminating protein modification and degradation arising from exposure to UV light
|
|
EP2771031B1
(en)
|
2011-10-28 |
2018-04-18 |
Prothena Biosciences Limited |
Humanized antibodies that recognize alpha-synuclein
|
|
EP2807188B1
(en)
|
2012-01-27 |
2019-09-11 |
Prothena Biosciences Limited |
Humanized antibodies that recognize alpha-synuclein
|
|
AR094821A1
(es)
*
|
2012-07-25 |
2015-09-02 |
Hanmi Pharm Ind Co Ltd |
Formulación líquida de un conjugado de péptido insulinotrópico de acción prolongada
|
|
AR092862A1
(es)
*
|
2012-07-25 |
2015-05-06 |
Hanmi Pharm Ind Co Ltd |
Formulacion liquida de insulina de accion prolongada y un peptido insulinotropico y metodo de preparacion
|
|
AR091902A1
(es)
*
|
2012-07-25 |
2015-03-11 |
Hanmi Pharm Ind Co Ltd |
Formulacion liquida de un conjugado de insulina de accion prolongada
|
|
UA118441C2
(uk)
|
2012-10-08 |
2019-01-25 |
Протена Біосаєнсиз Лімітед |
Антитіло, що розпізнає альфа-синуклеїн
|
|
MX2015006997A
(es)
|
2012-12-26 |
2015-09-23 |
Wockhardt Ltd |
Composicion farmaceutica.
|
|
US20140255413A1
(en)
|
2013-03-07 |
2014-09-11 |
Boehringer Ingelheim International Gmbh |
Combination therapy for neoplasia treatment
|
|
US9700485B2
(en)
|
2013-04-24 |
2017-07-11 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
|
NL1040254C2
(en)
*
|
2013-05-17 |
2014-11-24 |
Ablynx Nv |
Stable formulations of immunoglobulin single variable domains and uses thereof.
|
|
US10513555B2
(en)
|
2013-07-04 |
2019-12-24 |
Prothena Biosciences Limited |
Antibody formulations and methods
|
|
US9732154B2
(en)
|
2014-02-28 |
2017-08-15 |
Janssen Biotech, Inc. |
Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
|
|
US9603927B2
(en)
|
2014-02-28 |
2017-03-28 |
Janssen Biotech, Inc. |
Combination therapies with anti-CD38 antibodies
|
|
US10562973B2
(en)
|
2014-04-08 |
2020-02-18 |
Prothena Bioscience Limited |
Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein
|
|
PE20171094A1
(es)
|
2014-12-04 |
2017-08-07 |
Janssen Biotech Inc |
Anticuerpos anti-cd38 para el tratamiento de la leucemia linfoblastica aguda
|
|
SG11201705484WA
(en)
*
|
2015-02-09 |
2017-08-30 |
Ucb Biopharma Sprl |
Pharmaceutical formulation
|
|
CR20170526A
(es)
|
2015-05-20 |
2018-04-03 |
Janssen Biotech Inc |
ANTICUERPOS ANTI-CD38 PARA EL TRATAMIENTO DE AMILOIDOSIS DE CADENA LIGERA y OTRAS ENFERMEDADES MALIGNAS HEMATOLÓGICAS POSITIVAS PARA CD38
|
|
AR104847A1
(es)
*
|
2015-06-17 |
2017-08-16 |
Lilly Co Eli |
Formulación de anticuerpo anti-cgrp
|
|
US20170044265A1
(en)
|
2015-06-24 |
2017-02-16 |
Janssen Biotech, Inc. |
Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
|
|
JP7027321B2
(ja)
|
2015-11-03 |
2022-03-01 |
ヤンセン バイオテツク，インコーポレーテツド |
抗ｃｄ３８抗体の皮下製剤及びその使用
|
|
JP6992262B2
(ja)
*
|
2016-03-31 |
2022-02-15 |
東ソー株式会社 |
変性抗体測定試薬の製造方法
|
|
WO2018002181A1
(en)
|
2016-06-28 |
2018-01-04 |
Umc Utrecht Holding B.V. |
TREATMENT OF IgE-MEDIATED DISEASES WITH ANTIBODIES THAT SPECIFICALLY BIND CD38
|
|
CA3044082A1
(en)
|
2017-04-03 |
2018-10-11 |
Immunomedics, Inc. |
Subcutaneous administration of antibody-drug conjugates for cancer therapy
|
|
US11618787B2
(en)
|
2017-10-31 |
2023-04-04 |
Janssen Biotech, Inc. |
Methods of treating high risk multiple myeloma
|
|
PE20212185A1
(es)
|
2019-02-18 |
2021-11-11 |
Lilly Co Eli |
Formulacion de anticuerpos terapeuticos
|
|
CN112206320B
(zh)
*
|
2019-07-12 |
2025-02-25 |
鲁南制药集团股份有限公司 |
一种cd47单克隆抗体冻干粉制剂及其制备工艺
|
|
US12558423B2
(en)
|
2020-05-29 |
2026-02-24 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody-containing formulation
|
|
CN113967195A
(zh)
*
|
2020-07-22 |
2022-01-25 |
三生国健药业（上海）股份有限公司 |
抗her2/pd1双特异性抗体冻干制剂及其制备方法
|